US Patent

US10154987 — Enalapril formulations

Method of Use · Assigned to Silvergate Pharmaceuticals Inc · Expires 2036-03-25 · 10y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable enalapril oral liquid formulations and methods of using them to treat hypertension, heart failure, and asymptomatic left ventricular dysfunction.

USPTO Abstract

Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.

Drugs covered by this patent

Vasotec (ENALAPRIL MALEATE) · Azurity

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3`	Treatment of inflammatory conditions	Vasotec

Patent Metadata

Patent number: US10154987
Jurisdiction: US
Classification: Method of Use
Expires: 2036-03-25
Drug substance claim: No
Drug product claim: No
Assignee: Silvergate Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.